Background/aim A post‐marketing surveillance (PMS) study is being conducted to
investigate the safety and effectiveness of the long‐term use of dabigatran etexilate …

Background There is little evidence of the efficacy and safety of dabigatran in Japanese
patients with non‐valvular atrial fibrillation (NVAF). Methods and Results We evaluated 300 …

Background—During follow-up of between 1 and 3 years in the Randomized Evaluation of
Long-term Anticoagulation Therapy (RE-LY) trial, 2 doses of dabigatran etexilate were …

Background: RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) is an
international multicenter study (18,113 patients from 967 centers in 44 countries) that …

Background A blue letter (safety advisory) for dabigatran was issued by the Japanese
Ministry of Health, Labour and Welfare in August 2011. Changes in physicians' attitudes …

Background: Dabigatran was shown effective for stroke prevention in atrial fibrillation (AF) in
RE-LY; and RELY-ABLE provided additional follow-up of dabigatran. Combining these two …

GLORIA-AF is a large, ongoing, prospective, global registry program run in 3 phases,
assessing long-term safety and effectiveness of dabigatran etexilate (dabigatran) in patients …

The effectiveness and safety of dabigatran for stroke prevention in atrial fibrillation (SPAF)
demonstrated in RE-LY needs to be confirmed in daily care. To evaluate treatment …

Dabigatran is an oral direct thrombin inhibitor (DTI), which has a rapid onset of action and
can be given twice daily (bid) without anticoagulation monitoring. To determine the long term …

BACKGROUND: Dabigatran is a recently introduced direct thrombin inhibitor licensed for
use as an oral anticoagulant for stroke prevention in non-valvular atrial fibrillation. Our …